Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 62.52 | 49.06 | 40.83 | 61.26 | 57.95 | — | 104.70 | 81.85 | 95.15 | 71.65 | 56.77 | 113.47 | 54.90 | 43.42 | 43.13 | 66.84 | 32.27 | 57.01 | 73.15 | 65.99 | 72.11 |
| — | — | -61.0% | -25.2% | -39.1% | — | +84.4% | -27.9% | +73.3% | +65.0% | +31.6% | +69.8% | +70.1% | -23.8% | -41.0% | +1.3% | -55.2% | -81.5% | -14.2% | -3.6% | -2.2% | |
| P/S Ratio | 9.34 | 8.63 | 6.58 | 7.80 | 7.59 | 6.32 | 7.37 | 9.74 | 11.12 | 9.40 | 9.31 | 11.33 | 9.95 | 10.97 | 10.19 | 12.34 | 10.67 | 12.30 | 15.27 | 19.79 | 19.35 |
| — | +36.6% | -10.6% | -19.9% | -31.8% | -32.8% | -20.8% | -14.0% | +11.8% | -14.3% | -8.7% | -8.2% | -6.8% | -10.8% | -33.3% | -37.7% | -44.8% | -30.9% | -4.2% | +38.9% | +59.4% | |
| P/B Ratio | 5.35 | 5.26 | 3.93 | 4.59 | 4.42 | 4.18 | 4.62 | 5.57 | 6.02 | 5.56 | 5.61 | 6.29 | 5.52 | 6.72 | 6.35 | 7.34 | 6.58 | 8.33 | 10.35 | 12.52 | 12.11 |
| — | +26.0% | -14.8% | -17.5% | -26.5% | -24.9% | -17.7% | -11.5% | +9.1% | -17.2% | -11.6% | -14.3% | -16.1% | -19.4% | -38.7% | -41.4% | -45.7% | -29.0% | +3.2% | +49.9% | +75.8% | |
| P/FCF | 43.14 | 31.90 | 26.43 | 30.18 | 97.86 | 21.47 | 75.16 | 37.31 | 58.84 | 50.03 | 43.76 | 45.24 | 60.18 | 45.54 | 77.28 | 57.51 | 61.87 | 39.76 | 76.43 | 58.68 | 117.69 |
| — | +48.6% | -64.8% | -19.1% | +66.3% | -57.1% | +71.8% | -17.5% | -2.2% | +9.9% | -43.4% | -21.3% | -2.7% | +14.5% | +1.1% | -2.0% | -47.4% | -4.5% | +26.5% | +42.9% | +161.5% | |
| EV / EBITDA | 32.54 | 28.24 | 20.78 | 29.72 | 31.07 | 637.92 | 36.22 | 39.55 | 48.03 | 39.86 | 30.89 | 48.54 | 33.84 | 27.77 | 28.78 | 35.76 | 35.23 | 33.66 | 38.66 | 61.35 | 57.20 |
| — | -95.6% | -42.6% | -24.9% | -35.3% | +1500.6% | +17.3% | -18.5% | +42.0% | +43.5% | +7.3% | +35.7% | -4.0% | -17.5% | -25.6% | -41.7% | -38.4% | -32.7% | -11.3% | +36.5% | +58.3% | |
| EV / EBIT | 45.11 | 41.02 | 27.81 | 44.43 | 43.93 | — | 59.59 | 65.45 | 77.27 | 66.67 | 44.75 | 84.68 | 52.45 | 36.66 | 37.81 | 44.33 | 27.19 | 43.93 | 62.82 | 60.22 | 71.07 |
| — | — | -53.3% | -32.1% | -43.2% | — | +33.2% | -22.7% | +47.3% | +81.9% | +18.4% | +91.0% | +92.9% | -16.6% | -39.8% | -26.4% | -61.7% | -90.2% | -22.9% | +11.7% | +22.6% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.8% | 65.8% | 66.9% | 64.6% | 65.6% | 62.7% | 67.9% | 65.3% | 63.2% | 66.4% | 67.4% | 64.8% | 66.9% | 67.9% | 68.7% | 67.5% | 66.6% | 69.5% | 69.4% | 68.2% | 66.4% |
| — | +4.9% | -1.4% | -1.0% | +3.8% | -5.6% | +0.6% | +0.8% | -5.4% | -2.2% | -1.9% | -4.1% | +0.4% | -2.3% | -0.9% | -1.0% | +0.4% | +2.3% | +0.4% | +1.4% | -1.6% | |
| Operating Margin | 20.7% | 23.1% | 24.2% | 18.4% | 16.6% | -7.5% | 12.2% | 16.0% | 13.8% | 15.0% | 22.1% | 13.9% | 20.2% | 31.4% | 27.3% | 25.0% | 20.9% | 28.0% | 31.1% | 23.2% | 24.5% |
| — | +407.2% | +98.0% | +15.3% | +20.4% | -150.3% | -44.6% | +14.5% | -31.5% | -52.3% | -19.0% | -44.2% | -3.4% | +12.2% | -12.5% | +8.0% | -14.9% | +5.6% | +10.5% | +1.8% | +2.0% | |
| Net Margin | 15.0% | 17.0% | 16.4% | 12.8% | 13.3% | -5.6% | 7.1% | 11.7% | 11.6% | 13.3% | 16.2% | 10.1% | 18.4% | 25.1% | 23.9% | 18.4% | 33.2% | 21.3% | 20.9% | 29.8% | 27.0% |
| — | +404.9% | +129.5% | +9.4% | +14.8% | -142.1% | -55.8% | +16.6% | -37.0% | -47.1% | -32.3% | -45.3% | -44.6% | +17.4% | +14.1% | -38.2% | +22.9% | +269.6% | +11.3% | +44.3% | +65.2% |
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.0% | 2.6% | 2.5% | 1.9% | 2.0% | -0.9% | 1.1% | 1.7% | 1.6% | 2.0% | 2.5% | 1.4% | 2.6% | 3.9% | 3.8% | 2.8% | 5.2% | 3.6% | 3.6% | 4.8% | 4.3% |
| — | +390.0% | +126.0% | +15.5% | +23.1% | -145.2% | -55.3% | +19.3% | -37.9% | -49.2% | -34.7% | -50.4% | -50.4% | +8.6% | +6.2% | -41.6% | +19.9% | +275.7% | +19.6% | +53.6% | +82.7% | |
| ROA | 7.1% | 2.1% | 2.0% | 1.5% | 1.5% | -0.7% | 0.9% | 1.3% | 1.2% | 1.5% | 1.8% | 1.0% | 1.9% | 2.9% | 2.8% | 2.1% | 3.9% | 2.7% | 2.6% | 3.5% | 3.1% |
| — | +412.8% | +136.8% | +16.7% | +21.6% | -145.4% | -52.8% | +28.9% | -34.7% | -48.1% | -36.4% | -52.8% | -51.0% | +7.6% | +7.3% | -39.5% | +25.5% | +289.1% | +19.6% | +56.1% | +87.7% | |
| ROIC | 8.7% | 2.6% | 2.6% | 1.9% | 1.6% | -0.8% | 1.3% | 1.5% | 1.3% | 1.5% | 2.1% | 1.2% | 1.8% | 3.2% | 2.9% | 2.6% | 2.2% | 3.2% | 3.6% | 2.5% | 2.6% |
| — | +426.0% | +105.9% | +21.2% | +26.5% | -154.4% | -40.2% | +28.6% | -29.1% | -53.9% | -26.5% | -54.6% | -19.1% | -2.2% | -21.2% | +3.0% | -14.7% | +8.5% | +17.7% | +11.2% | +18.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.14 | 0.14 | 0.17 | 0.20 | 0.23 | 0.21 | 0.19 | 0.19 | 0.20 | 0.25 | 0.28 | 0.28 | 0.23 | 0.25 | 0.16 | 0.20 | 0.19 | 0.19 | 0.21 | 0.23 |
| — | -40.7% | -33.7% | -8.2% | +7.6% | +14.1% | -14.6% | -32.8% | -32.2% | -12.3% | -2.1% | +78.8% | +41.0% | +20.7% | +31.3% | -23.4% | -14.9% | -28.4% | +1.0% | +3.6% | -17.4% | |
| Debt / EBITDA | 0.78 | 2.94 | 2.91 | 4.43 | 5.48 | 136.59 | 6.39 | 5.30 | 5.86 | 5.68 | 5.25 | 8.44 | 6.51 | 3.75 | 4.42 | 3.06 | 4.12 | 3.06 | 2.83 | 4.02 | 4.29 |
| — | -97.8% | -54.4% | -16.4% | -6.4% | +2305.4% | +21.8% | -37.2% | -10.1% | +51.6% | +18.6% | +176.2% | +58.1% | +22.3% | +56.5% | -24.0% | -4.0% | -32.1% | -13.4% | -5.3% | -24.6% | |
| Current Ratio | 4.55 | 4.55 | 4.49 | 4.54 | 4.22 | 3.46 | 3.71 | 3.94 | 4.56 | 3.87 | 4.08 | 4.37 | 4.63 | 4.84 | 4.04 | 4.40 | 4.01 | 3.44 | 3.55 | 3.81 | 4.06 |
| — | +31.5% | +21.1% | +15.3% | -7.6% | -10.7% | -9.1% | -9.9% | -1.4% | -19.9% | +0.8% | -0.8% | +15.4% | +40.6% | +13.8% | +15.5% | -1.2% | +2.6% | -13.6% | -17.3% | -21.1% | |
| Quick Ratio | 3.35 | 3.35 | 3.18 | 3.08 | 2.81 | 2.38 | 2.58 | 2.77 | 3.26 | 2.75 | 2.88 | 3.03 | 3.17 | 3.50 | 2.84 | 3.15 | 2.92 | 2.64 | 2.79 | 3.03 | 3.18 |
| — | +40.7% | +23.2% | +11.2% | -13.8% | -13.3% | -10.4% | -8.7% | +2.8% | -21.5% | +1.2% | -3.9% | +8.6% | +32.7% | +2.1% | +4.2% | -8.2% | +2.0% | -16.0% | -18.3% | -23.0% | |
| Interest Coverage | 45.53 | 23.19 | 23.11 | 24.39 | 17.36 | -9.50 | 20.07 | 20.96 | 19.46 | 17.60 | 16.25 | 8.71 | 11.13 | 24.86 | 59.67 | 32.38 | 28.37 | 32.56 | 28.59 | 30.70 | 20.77 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TECH stock.
Bio-Techne Corporation's current P/E is 62.5x. The average P/E over the last 4 quarters is 52.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bio-Techne Corporation's current operating margin is 20.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bio-Techne Corporation's business trajectory between earnings reports.